Placebo News and Research

RSS

Pulmatrix reports positive results from initial PUR0200 Phase IB clinical study in COPD

Pulmatrix today announced the successful completion and positive results of the first part of a two-part Phase IB clinical study in chronic obstructive pulmonary disease (COPD) patients with their lead clinical candidate PUR0200.

29 Oct 2013

Biogen Idec Q3 total revenues increase 32% to $1.8 billion

Biogen Idec Inc. today reported third quarter 2013 total revenues of $1.8 billion, an increase of 32% over the third quarter of 2012. Non-GAAP diluted EPS for the third quarter of 2013 were $2.35, an increase of 23% over the third quarter of 2012.

28 Oct 2013

Delaying rheumatoid arthritis treatment could greatly increase likelihood of joint damage

Delaying treatment for rheumatoid arthritis could greatly increase the likelihood that patients will suffer joint damage and experience disability two years out, according to a new study from Vivian Bykerk, M.D. at Hospital for Special Surgery. The research will be presented at the annual meeting of the American College of Rheumatology/Association of Rheumatology Health Professionals on October 28 in San Diego.

28 Oct 2013

Apremilast drug shows promise for Behcet's ulcers

Apremilast, an orally available small molecule modulating several inflammatory pathways, which is pending approval by the United States Food and Drug Administration, is showing promise in the treatment of mouth and genital ulcers in people with Behcet's syndrome, according to research presented this week at the American College of Rheumatology Annual Scientific Meeting in San Diego.

28 Oct 2013

Two aggressive therapy approaches effective for children with juvenile idiopathic arthritis

Children with juvenile idiopathic arthritis who receive early, aggressive therapy with a combination of medications achieve clinical inactive disease status faster than they would with less aggressive therapy, according to new research presented this week at the American College of Rheumatology Annual Meeting in San Diego.

28 Oct 2013

Scientists develop new drug to treat obstructive airway diseases

Scientists have developed a new drug (RPL554) that could treat obstructive airway diseases such as asthma and chronic obstructive pulmonary disease in two ways at once, according to new research published in The Lancet Respiratory Medicine.

25 Oct 2013

Study: Investigational drug shows promise against pancreatic cancer

An investigational drug that disrupts tumor blood vessels shows promise against a rare type of pancreatic cancer, scientists at Albert Einstein College of Medicine of Yeshiva University have found. Their results were presented October 20 during a poster session at an international cancer conference.

25 Oct 2013

Study shows oxytocin hormone enhances placebo response in analgesia model

The hormone oxytocin may mediate processes such as empathy, trust, and social learning. These are key elements of the patient-physician relationship, which is an important mediator of placebo responses, according to background information in a Research Letter appearing in the October 23/30 issue of JAMA.

24 Oct 2013

FDA grants Priority Review to Lilly's ramucirumab for treatment of advanced gastric cancer

Eli Lilly and Company today announced that the U.S. Food and Drug Administration has assigned Priority Review to the regulatory submission for ramucirumab (IMC-1121B) as a single-agent treatment for advanced gastric cancer following disease progression after initial chemotherapy.

23 Oct 2013

Influenza vaccination linked with reduced risk of adverse cardiovascular events

Receiving an influenza vaccination was associated with a lower risk of major adverse cardiovascular events such as heart failure or hospitalization for heart attack, with the greatest treatment effect seen among patients with recent acute coronary syndrome (ACS; such as heart attack or unstable angina), according to a meta-analysis published in the October 23/30 issue of JAMA.

23 Oct 2013

Clinical trial to investigate if vitamin D supplement helps prevent type 2 diabetes

Researchers have begun the first definitive, large-scale clinical trial to investigate if a vitamin D supplement helps prevent or delay type 2 diabetes in adults who have prediabetes, who are at high risk for developing type 2. Funded by the National Institutes of Health, the study is taking place at about 20 study sites across the United States.

23 Oct 2013

REGARD VEGF receptor-2 as gastric cancer target

Targeting vascular endothelial growth factor receptor-2 mediated signaling is an effective strategy against advanced gastric cancer, results from the REGARD trial demonstrate.

22 Oct 2013

AstraZeneca begins selumetinib Phase 3 clinical trial in NSCLC patients

AstraZeneca today announced the first patient randomized in a Phase 3 clinical trial for selumetinib, an oral, potent, selective MEK inhibitor, being investigated as second-line therapy in patients with advanced or metastatic non-small-cell lung cancer whose tumors are KRAS mutation-positive.

22 Oct 2013

COPD treatments: an interview with Professor Price, University of Aberdeen

The first thing is that we can’t cure COPD. The problem we have with COPD is that the process itself is not treatable, certainly not once it gets to the extent that it’s advanced.

22 Oct 2013

Clinical trial to determine whether vitamin D helps prevent or delay development of type 2 diabetes

UT Southwestern Medical Center researchers are seeking 150 to 200 adults to take part in the local arm of a major national clinical trial that will investigate whether vitamin D helps prevent or delay development of type 2 diabetes.

22 Oct 2013

NeuroAiD reduces early cardiovascular events and deaths by 50% after stroke onset

NeuroAiD™, a treatment of post-stroke recovery containing natural extracts, reduces early cardiovascular events and deaths by nearly 50% on top of antiplatelet agents within three months after stroke onset, without an increase in bleeding rate and non-vascular deaths according to research published online in the journal Stroke.

22 Oct 2013

FDA approves SC formulation of Genentech's Actemra for rheumatoid arthritis

Genentech, a member of the Roche Group, today announced that the U.S. Food and Drug Administration has approved a subcutaneous formulation of Actemra (tocilizumab) for the treatment of adults with moderately to severely active rheumatoid arthritis who have used one or more disease-modifying antirheumatic drugs, such as methotrexate, that did not provide enough relief.

22 Oct 2013

Researchers receive NIH grant to conduct Vitamin D and Type 2 diabetes study

A research team led by Anastassios G. Pittas, MD, MS, Endocrinologist and Co-Director of the Diabetes Center at Tufts Medical Center in Boston, has received a National Institutes of Health grant of more than $40 million over five years to conduct the Vitamin D and Type 2 diabetes study.

22 Oct 2013

FDA approves Cubist Pharmaceuticals' sNDA for ENTEREG

Cubist Pharmaceuticals, Inc. today announced the approval of its supplemental new drug application (sNDA) by the U.S. Food and Drug Administration for ENTEREG (alvimopan).

21 Oct 2013

COPD investigational treatments: an interview with Dr. Tunde Otulana, Senior Vice President, Clinical Development and Medical Affairs, Boehringer Ingelheim Pharmaceuticals, Inc.

Olodaterol is a long-acting beta2-agonist (LABA) bronchodilator delivered via the Respimat® inhaler. It is being investigated as a once daily maintenance bronchodilator treatment of airflow obstruction in patients with chronic obstructive pulmonary disease (COPD), including chronic bronchitis and/or emphysema.

21 Oct 2013

Placebo News and Research

Pulmatrix reports positive results from initial PUR0200 Phase IB clinical study in COPD

Biogen Idec Q3 total revenues increase 32% to $1.8 billion

Delaying rheumatoid arthritis treatment could greatly increase likelihood of joint damage

Apremilast drug shows promise for Behcet's ulcers

Two aggressive therapy approaches effective for children with juvenile idiopathic arthritis

Scientists develop new drug to treat obstructive airway diseases

Study: Investigational drug shows promise against pancreatic cancer

Study shows oxytocin hormone enhances placebo response in analgesia model

FDA grants Priority Review to Lilly's ramucirumab for treatment of advanced gastric cancer

Influenza vaccination linked with reduced risk of adverse cardiovascular events

Clinical trial to investigate if vitamin D supplement helps prevent type 2 diabetes

REGARD VEGF receptor-2 as gastric cancer target

AstraZeneca begins selumetinib Phase 3 clinical trial in NSCLC patients

COPD treatments: an interview with Professor Price, University of Aberdeen

Clinical trial to determine whether vitamin D helps prevent or delay development of type 2 diabetes

NeuroAiD reduces early cardiovascular events and deaths by 50% after stroke onset

FDA approves SC formulation of Genentech's Actemra for rheumatoid arthritis

Researchers receive NIH grant to conduct Vitamin D and Type 2 diabetes study

FDA approves Cubist Pharmaceuticals' sNDA for ENTEREG

COPD investigational treatments: an interview with Dr. Tunde Otulana, Senior Vice President, Clinical Development and Medical Affairs, Boehringer Ingelheim Pharmaceuticals, Inc.

Advancing Neuroscience Research Through Collaboration and Patient-Centered Innovation

The impact of vibration on microscopy

How Omics Technologies Are Transforming Biological Research and Drug Discovery

Latest News